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Abstract 
 
Post-traumatic stress disorder (PTSD) is a common mental disorder associated with significant distress and 
reduced functioning. Its occurrence after a severe traumatic event and association with characteristic neuro-
biological changes make PTSD a good candidate for pharmacological prevention and early treatment. The 
primary aim for this systematic review and meta-analysis was to assess whether pharmacological 
interventions when compared to placebo, or other pharmacological/psychosocial interventions re-
sulted in a clinically significant reduction or prevention of symptoms, improved functioning or 
quality of life, presence of disorder, or adverse effects. A systematic search was undertaken to identify 
RCTs, which used early pharmacotherapy (within three months of a traumatic event) to prevent and treat 
PTSD and Acute Stress Disorder (ASD) in children and adults. Using Cochrane Collaboration methodology, 
RCTs were identified and rated for risk of bias.  Available data was pooled to calculate risk ratios (RR) for 
PTSD prevalence and standardised mean differences (SMD) for PTSD severity. 19 RCTs met the inclusion 
criteria; 16 studies with adult participants and three with children. The methodological quality of most trials 
was low. Only hydrocortisone in adults was found to be superior to placebo (3 studies, n= 88, RR: 0.21 (CI 
0.05 to 0.89)) although this was in populations with severe physical illness, raising concerns about generali-
sability. No significant effects were found for the other pharmacotherapies investigated (propranolol, oxyto-
cin, gabapentin, fish oil (1,470mg DHA/147mg EPA), fish oil (224mg DHA/22.4mg EPA), dexamethasone, 
escitalopram, imipramine and chloral hydrate). Hydrocortisone shows the most promise, of pharmacothera-
pies subjected to RCTs, as an emerging intervention in the prevention of PTSD within three months after 
trauma and should be a target for further investigation. The limited evidence for hydrocortisone and its ad-
verse effects mean it cannot be recommended for routine use, but, it could be considered as a preventative 
intervention for people with severe physical illness or injury, shortly after a traumatic event, as long as there 
are no contraindications. More research is needed using larger, high quality RCTs to establish the most effi-
cacious use of hydrocortisone in different populations and optimal dosing, dosing window and route. There 
is currently a lack of evidence to suggest that other pharmacological agents are likely to be effective. 
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Introduction 
Post-traumatic Stress Disorder (PTSD) is a common mental disorder manifesting through symptoms of re-
experiencing, hyper-arousal and avoidance following a traumatic event. In high-risk populations the preva-
lence of PTSD is estimated at 15.4%1. PTSD is associated with substantial physical and psychiatric co-mor-
bidity, including substance abuse and suicide2. The DSM-5 states that symptoms must be present for one 
month following the traumatic event for PTSD to be diagnosed3. Acute Stress Disorder (ASD) has similar 
symptoms to PTSD, is diagnosed 3 days to 1 month post-trauma and is a good predictor of PTSD4. Therapies 
to prevent early traumatic stress reactions developing into chronic PTSD, particularly in high-risk individu-
als, are needed to alleviate this significant morbidity. 
 
While some psychological interventions to prevent the development of PTSD are ineffective5 and others, 
such as psychological debriefing after trauma may even be harmful6, there is evidence of benefit of trauma-
focused cognitive behavioural therapy in treating individuals with acute traumatic stress symptoms7 and pre-
liminary work on prolonged exposure therapy in the immediate aftermath of trauma, has shown promise in 
the reduction of post-traumatic stress reactions8. The limited evidence available for treatments incorporating 
both psychological and pharmacological intervention, however, has so far failed to show significant benefit9. 
 
As our scientific understanding of the neurobiological changes occurring during PTSD onset has increased, 
more research has focused on pharmacological interventions to prevent PTSD. For example, the finding that 
memory consolidation appears particularly vulnerable to disruption in the six hours after trauma10, makes the 
shifts in neurobiological activity in these ‘golden hours’11 and beyond a promising target for pharmacologi-
cal intervention12. 
 
Early research explored the effects of benzodiazepine administration and was largely ineffective13. Later re-
search has focused on B-blockers, such as propranolol, and their ability to disrupt post-synaptic norepineph-
rine receptors14. Studies have suggested that human participants who received propranolol have decreased 
recall of emotionally stimulating material, possibly due to the blocking of memory consolidation15 and subse-
quent studies have explored the efficacy of propranolol as a preventive agent16. 
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Other studies have found an association between low cortisol levels following motor vehicle accidents and 
subsequent PTSD17, 18. Both human and animal studies suggest that glucocorticoids attenuate heightened fear 
response19 through increased removal of fear inducing memories20 resulting in interest in the potential pre-
ventive effects of hydrocortisone. 
 
In addition to propranolol and hydrocortisone, observational studies have associated early morphine use with 
reduced rates of PTSD21 and other drugs, including SSRIs22, gabapentin23, α-omega fatty acids24 and keta-
mine25 have also been investigated for the prevention of PTSD. Previous systematic reviews in this area have 
highlighted both the sparsity and the poor quality of the trials24, 26. Sijbrandij et al. 26 included randomised 
controlled trials (RCTs), controlled clinical trials and cohort studies to maximise the number of included 
studies. After the meta-analyses of Sijbrandij et al. 26 and Amos et al. 24 more recent studies have been pub-
lished, such as a study on escitalopram22 and a study on oxytocin27. In order to determine if the evidence has 
developed in the last few years, we undertook a further systematic review and meta-analysis, building on the 
original review of Sijbrandij et al.26 but only including RCTs. The inclusion of just RCTs allowed us to focus 
on a higher quality of evidence to offer sound recommendations for future research. Another difference is 
that we included studies which administered the intervention within the first three months instead of just one 
month of the trauma. The study was conducted to update the International Society of Traumatic Stress Stud-
ies 2018 Treatment Guidelines28, the scoping question for which investigated early pharmacological inter-
vention within three months of the traumatic event. 
 
Thus the primary aim for this systematic review and meta-analysis was to assess whether pharmacological 
interventions when compared to placebo, or other pharmacological/psychosocial interventions resulted in a 
clinically significant reduction or prevention of symptoms, improved functioning or quality of life, presence 
of disorder, or adverse effects. We sought to analyse different classes of pharmacological agents separately, 
rather than pooling the data. 
 
Methods 
We adopted a methodology based on the Cochrane Handbook for Systematic Reviews of Interventions29 and 
a PRISMA checklist was completed. 
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Selection Criteria 
The inclusion criteria were: (a) any RCT (including cluster and cross-over trials); (b) investigating the effects 
of pharmacological intervention delivered within three months of the traumatic event; (c) when compared to 
placebo, pharmacological or psychosocial interventions; (d) in participants exposed to a traumatic event 
likely to meet the A criterion for DSM5 PTSD; and (e) PTSD or ASD symptoms measured using one or 
more validated clinician administered or self-report outcome measures. There was no restriction on the se-
verity of PTSD/ASD symptoms or the type of traumatic event, no restriction on sample size, and both pub-
lished and unpublished studies were eligible for inclusion. Only studies published in English were included. 
 
 
Search Strategy and Selection Criteria 
For this review we combined an updated search undertaken by the Cochrane Collaboration with the original 
search strategy from the review of Sijbrandij et al. 26 . This systematic review was undertaken alongside a 
number of other reviews carried out to update the ISTSS Treatment Guidelines28 . As part of this all RCTs 
related to the prevention and treatment of PTSD from 2013 to the 31st May 2018 were identified and scruti-
nised, producing 16 new papers on early pharmacotherapy considered in more detail here. For this updated 
search the inclusion criteria were reconsidered and subsequently much broader. The time frame for interven-
tion was extended to 3 months post-trauma. The original search strategy used PubMed, PsycINFO, Embase 
and the Cochrane database of randomised trials with no limitation on start date. Terms referring to PTSD 
were combined with terms referring to pharmacotherapy (using both MeSH terms and text words) and we 
also checked the references of four narrative reviews of pharmacological prevention of PTSD16, 12, 5, 30. De-
tails of the searches and exact search strings are provided in the appendix. 
 
All titles and abstracts were appraised by two independent screeners and any disagreements were dis-
cussed. The full text of any potentially relevant papers  was acquired and if we were unable to locate the full 
text for any study the corresponding author was contacted to request the paper. To determine if potentially 
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relevant studies met the inclusion criteria the full text was independently reviewed by two authors (LAW, 
JB). 
 
Data Extraction 
Data were extracted by two independent reviewers (LAW, JB) using identical data extraction forms. There 
were only minor irregularities between reviewers, which were discussed and consensus agreed on. Study au-
thors were contacted if more information was required. Basic demographic data and details of the interven-
tion used was collected along with primary outcomes of PTSD/ASD symptom severity and incidence.  
 
Assessment of Study Bias 
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials’31  was used for each identi-
fied study. This tool assesses the likelihood of bias in randomised trials, including the adequate generation of 
allocation sequence, acceptable concealment of allocation, satisfactory blinding of participants and person-
nel, and assessing the degree of incomplete outcome data. Risk of bias was assessed by two independent re-
viewers (LAW, JB) and any disagreement resolved by discussion. These ratings were considered and a 
GRADE judgement (which assesses quality of evidence to make recommendations for clinical practice32) 
was presented for each outcome. 
 
Synthesis of Results 
The primary outcome in the meta-analysis was reduction in PTSD symptoms 3 to 6 months after the trau-
matic event (but it was agreed a priori that the nearest time point to this would be accepted, and if there was 
no measure of PTSD symptoms, ASD symptoms would be included instead). This was performed using a 
random-effects model. PTSD incidence at 3 to 6 months after the traumatic event was also considered. For 
PTSD/ASD incidence we calculated risk ratios whereas for severity we calculated standardised mean differ-
ences, along with associated confidence intervals. For outcomes including more than one study we measured 
statistical heterogeneity by calculating the I2 statistic (t). As this was low for all results it did not change our 
analyses. Data was pooled if outcomes included two or more studies. Sub-group analyses were not per-
formed as there were few studies for individual outcomes. All analyses were done using the Cochrane Col-
laboration’s Review Manager 5.3 software33. 
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FIGURE ONE 
 
 
Results 
The initial search produced 2,139 papers. The updated search was broader and contained 5,500 additional 
papers. We examined the full text of 111 papers and 18 of these met the inclusion criteria. One other text 
which met the inclusion criteria was highlighted during peer review 54. The other 93 were excluded as per 
Figure 1. 
 
Our systematic review identified 19 RCTs with a total of 3629 participants. There were 16 adult RCTs34, 35, 36, 
37, 38, 16, 39, 40, 41, 23, 20, 27, 42, 43, 44, 54 (n = 3387) and 3 child RCTs45, 46, 47 (n = 242). 16 trials were included in the 
meta-analysis, with 3 excluded38, 40, 43 as they lacked sufficient information to include. For example, Schelling 
et al. 40 only included the median scores (with IQR) for PTSD severity. Tables 1 and 2 show detailed charac-
teristics of these trials. All studies focused on early intervention to prevent PTSD/ASD apart from Shalev et 
al. 35 and Suliman et al. 22 which were early treatment trials. Interventions were classified as early treatment 
trials if the intervention extended beyond the first month post trauma. Shalev et al. 41 initiated treatment with 
only those participants who met DSM-IV PTSD diagnostic criteria (assessed at a mean of 19.8 days post-
trauma). Similarly, Suliman et al. 22 included participants meeting the DSM IV criteria for full or partial 
ASD, initiating treatment within 28 days. When measuring outcomes from all trials, a clinician administered 
measure was used where available and self-report questionnaires if not35, 40, 42. 
 
 
TABLE ONE 
 
TABLE TWO 
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Seventeen studies compared effectiveness on PTSD outcomes, two studies on ASD severity23, 46. Robert et al. 
46 assessed ASD severity after administering imipramine to one group, and chloral hydrate to another, the 
participants were between 5 days and 148 days (mean: 36 days) post trauma (thermal injury). Robert et al. 46 
justified their use of ASD by arguing that acute hospitalisation for burns is continuously traumatising, and 
that the traumatic event continued until discharge. This is, however, debatable and at odds with commonly 
accepted definitions; PTSD would likely have been a more appropriate primary outcome to have measured. 
Stein et al.23 compared both ASD and PTSD outcomes, finding no significant difference across the three 
groups - propranolol, gabapentin and placebo. 
 
Risk of Bias Assessments 
The quality of the RCTs was highly variable and the majority of the studies had areas of significant risk of 
bias in their methodology (explored in Supplementary Table 1 and Supplementary Table 2). Only four stud-
ies27, 37, 38, 54 used intention-to-treat (ITT) analysis with the other 15 studies using completer-only analysis 
(Suliman et al.22 used a modified ITT analysis, with only completer-only analysis reported and, therefore, 
used in this meta-analysis and so it is not considered a true ITT trial). 
 
Meta-analyses 
The results of our meta-analyses are shown in tables 3 and 4. Rosenberg et al.47 and Sharp et al.48 used the 
same data set with different follow up periods, because of this we included the Rosenberg et al. study47 
which used PTSD outcomes. Sharp et al.48 used ASD outcomes and also noted no significant difference be-
tween control and treatment groups. 
 
 
TABLE THREE 
 
TABLE FOUR 
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A small positive effect was found for hydrocortisone over placebo on PTSD severity.  A larger, but still 
modest, effect was found for hydrocortisone over placebo on PTSD incidence. The forest plots demonstrat-
ing these outcomes are shown in Supplementary Figure 1 and 2. 
 
 
Discussion 
This systematic review identified 19 RCTs with 16 included in the meta-analysis and found some evidence 
for the potential efficacy of hydrocortisone in the prevention of PTSD in adults. There was no evidence to 
support the efficacy of propranolol in terms of prevention of PTSD or ASD. Considering the paucity of evi-
dence available, it remains difficult to draw firm conclusions on other agents, although no RCT was able to 
demonstrate an overall beneficial effect without sub-group analysis. 
 
Our results mirror those of previous systematic reviews24, 26. Sijbrandij et al. 26 identified 15 studies and eval-
uated 10 pharmacotherapies while we evaluated 19 and nine respectively. We were unable to evaluate mor-
phine, for which observational studies have associated morphine administration with a decreased PTSD inci-
dence21, as there were no RCTs but were able to assess oxytocin, fish oil (1,470mg DHA/147mg EPA) and 
fish oil (224mg DHA/22.4mg EPA) due to new evidence. Amos et al. 2014 evaluated four hydrocortisone 
trials, while Sijbrandij et al. 26 assessed five, and we included six34, 35, 39, 40, 42, 11 (with three in the meta-analy-
sis34, 42, 11). This accumulation of evidence shows continuing interest in evaluating hydrocortisone. 
 
Initiating a therapy within the first six hours post-trauma is thought to be crucial to impeding the disruption 
to memory consolidation that occurs within this period. Ten studies initiated therapy within 12 hours34, 35, 36, 
45, 16, 39, 40, 42, 43, 54 - three of propranolol 36, 45, 16, six of hydrocortisone 34, 35, 39, 40, 42, 43, one of dexamethasone 54. 
Five of these hydrocortisone trials35, 39, 40, 42, 43 initiated therapy within the “golden” six hours, while De-
lahanty et al. 34 administered hydrocortisone within a 12-hour window and their results suggest that hydro-
cortisone may still be effective in preventing PTSD outside of a six-hour window. Only one propranolol trial 
initiated pharmacotherapy within six hours16 and similarly to those initiating therapy later on, also failed to 
show a preventative effect on PTSD. It remains possible, however, that earlier administration may be more 
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effective in blocking memory consolidation, although the efficacy of hydrocortisone administration at be-
yond 6 hours appears to contradict this, in addition to a limited theoretical basis. It is also likely that memory 
consolidation is not the only neurobiological process causing PTSD and pharmacological agents may act via 
different mechanisms or more than one mechanism, oxytocin for example is an anxiolytic in addition to pos-
sibly affecting memory consolidation27. Disruption of other causative pathways may produce new avenues 
for pharmacological prevention. 
 
Pragmatically, it is difficult to identify, consent and enroll a participant into a RCT within six hours of an 
unexpected trauma, with many studies thus investigating expected trauma (e.g. Intensive Therapy Unit (ITU) 
admission, cardiac surgery). Hydrocortisone remains a potentially promising intervention for PTSD and is 
particularly well suited to trauma that necessitates prompt presentation to a hospital setting such as severe 
injury. Furthermore there is scope for large scale administration in a low resource setting, given its wide-
spread availability as an WHO essential medicine49 and its low cost. Given this, it may be better suited to a 
low resource or disaster setting than a more complicated psychosocial intervention. The possible necessity to 
administer it within a six-hour time window would hamper its use following many traumatic events and it is 
only likely to be of pragmatic use if future research confirms it is effective beyond the “golden hours”.  
 
Given the physical conditions of participants and acute hospital settings of the hydrocortisone trials to date, 
generalizability to other trauma populations is limited and it is possible that co-prescription of other drugs 
may have subjected the results to confounding. For example, inotropes like noradrenaline are frequently used 
in septic ITU patients39 and correlations have been found between chronic PTSD and raised urinary nora-
drenaline excretion50. It may be that noradrenaline tempers the effect of hydrocortisone and without endoge-
nous noradrenaline administration hydrocortisone may have a greater effect. Furthermore, dosing varied, 
from 20mg BD PO hydrocortisone34 to a 100mg IV bolus, followed by a continuous infusion with subse-
quent tapering42. Delahanty et al.’s 34 work suggested efficacy with an oral formulation, which if validated 
by subsequent research could increase the usability of hydrocortisone beyond secondary care and into low 
resource settings. 
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The analysis of escitalopram, gabapentin, oxytocin, fish oil (1,470mg DHA/147mg EPA) and fish oil 
(224mg DHA/22.4mg EPA) was limited by the paucity of studies. Only escitalopram was assessed by more 
than one study. None of these studies administered the treatment within six hours, and the two escitalopram 
studies were early treatment, not prevention, studies. It remains possible that earlier administration could be 
beneficial in preventing PTSD/ASD. Furthermore, the two fish oil studies used vastly different dosages, with 
neither showing a preventative effect. 
 
Many of the studies examined also investigated concurrent psychiatric comorbidity. Twelve investigated co-
existing depressive symptom severity22, 23, 27, 34, 36, 37, 42, 43, 44, 45, 47, 54, but the only significant differences ob-
served between control group and intervention were in those studies investigating hydrocortisone. Hydrocor-
tisone groups reported significantly less depressive symptoms in two studies - Delahanty et al.34 and Zohar et 
al.43. Zohar et al.43 also found fewer anxiety symptoms in the hydrocortisone group, while Delahanty et al.34 
found improvements in health related quality of life (HRQL) measures in the intervention group. Likewise, 
Weis et al.42 noted improvements in HRQL. It is possible that hydrocortisone administration may reduce sec-
ondary depressive symptoms indirectly by mediating the development of PTSD in traumatised individuals. It 
is also possible that attenuating the heightened fear response with hydrocortisone may prevent the formation 
of depression directly, in addition to PTSD. Regardless, both the amelioration of PTSD and depressive 
symptoms is likely to improve HRQL measures. Future hydrocortisone trials should attempt to measure both 
depression and PTSD outcomes to further understand this relationship. 
 
There was no apparent difference in effectiveness between interventions administered against placebo and 
those compared to a different comparator. Only two trials used a non-placebo comparator. Robert et al.46 
used chloral hydrate when investigating imipramine, while Nishi et al.38 used psychoeducation when investi-
gating fish oil (224mg DHA/22.4mg EPA). While both of these trials found no significant difference be-
tween the two interventions, their design does not allow conclusions to be drawn about actual efficacy as the 
effect sizes will have been influenced by the comparators’ effects on PTSD outcomes. Two other studies 
compared an intervention against standard treatment; Rosenberg et al.47 found no significant difference be-
tween propranolol and standard treatment, while Schelling et al.40 found a significant reduction in PTSD 
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symptoms in those treated with hydrocortisone. The magnitude of this result was similar to the other hydro-
cortisone trials but may have been exaggerated due to the absence of a placebo comparator group.  
 
Many of the RCTs included in our meta-analyses were small and the majority had areas of notable concern 
for risk of bias; both of these applied to the three RCTs evaluating hydrocortisone. No outcome received a 
GRADE rating higher than low. This, combined with the lack of studies for many outcomes, limits our confi-
dence in the best current evidence to determine the true effects of early pharmacological intervention to pre-
vent PTSD. This meta-analysis does, however, compile a higher quality of evidence than previously availa-
ble. 
 
Our work supports previous research investigating the preventative effect of hydrocortisone, but there re-
mains insufficient evidence to recommend its administration routinely.  Even in the short term, hydrocorti-
sone use can produce numerous adverse effects, ranging from congestive cardiac failure to insomnia. Of the 
studies we considered, some reported no side effects42, 43 while others reported dizziness34 and an increased 
rate of infection/septic shock, hyperglycaemia and hypernatraemia51, 35. As glucocorticoids have been widely 
used in medical practice for the past 60 years we have good knowledge of the adverse effects they cause, 
which may require further medical intervention. While we have sufficient knowledge of the adverse conse-
quences of giving hydrocortisone to people exposed to particular types of trauma, we must further under-
stand the potential benefits and risks in other groups of trauma victims and determine individual factors asso-
ciated with outcome. Furthermore, severe psychiatric side effects from corticosteroids occur in 6% of pa-
tients, with mild to moderate effects occurring in 28%52. The most common adverse effects are euphoria and 
hypomania, although no psychiatric adverse effects were documented in the hydrocortisone RCTs we exam-
ined. While side effects are more likely to develop in those requiring higher doses of corticosteroid, dosage 
does not predict the onset, duration or severity of the adverse reaction52. Nonetheless, this suggests caution 
should be used when prescribing higher dosing regimes. 4 RCTs did not exclude patients with a previous 
psychiatric history, but very limited information was available about the past psychiatric history of their par-
ticipants. Schelling et al.39, however, excluded patients with any psychiatric co-morbidity, and Zohar et al.43, 
excluded patients with a substance use disorder or history of brain trauma. Given the known side effect pro-
file of hydrocortisone, and the reassuring results of studies which did not exclude those with mental illness, 
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we conclude that there is no absolute contra-indication to hydrocortisone for those with pre-existing mental 
disorder. 
 
Thus, the potential benefit of the medication must be balanced against the potential side effects and patients 
may be reluctant to receive hydrocortisone in the absence of symptoms. Some of the included studies had 
problems recruiting participants34 and it is probable that a significant proportion of people may not be partic-
ularly willing to take medication to prevent PTSD. The reason for reluctance to take medication (with 42.6% 
refusing SSRI or placebo in one study41) is unclear and worthy of further exploration. Reluctance to take 
medication should not alter evidence-based recommendations to initiate safe and effective pharmacotherapy 
to prevent PTSD, although is very important with respect to considering implementation and should stimu-
late future research to consider acceptability in more depth. It seems likely that an optimal approach to offer-
ing preventative pharmacotherapy is to target those at highest risk of developing PTSD (for example, those 
who experienced peritraumatic dissociation) than offering intervention to all trauma-exposed individuals. 
The evidence examined in this paper suggests that certain agents may be more effective in certain sub-groups 
of individuals, for example Zohar et al. show the efficacy of escitalopram in victims of intentional trauma, 
while van Zuiden et al. observe the beneficial effects of oxytocin on trauma victims with high PTSD symp-
tom severity scores. While some of these trials used post-hoc sub-group analyses, this was not the case for all 
trials, with Delahanty et al.34, for example, including only participants with high levels of peritraumatic dis-
sociation. Thus, it is possible that preventative pharmacotherapy will be most efficacious in those at highest 
risk of developing PTSD, with more severe initial symptom severity. 
 
Similarly when examining dexamethasone, Kok et al. 54 found a lower prevalence of PTSD and depressive 
symptoms in women in the intervention group, but were unable to demonstrate lower PTSD/depression rates 
overall. The trial was the largest included in the meta-analysis, with 2458 participants, and used a stat dose 
of intravenous dexamethasone (dissimilar to all hydrocortisone trials which used regular administration). The 
study population was relatively healthy and only admitted to an ITU overnight, leaving them at low risk of 
developing PTSD compared to other trials and possibly explaining the failure of dexamethasone to prevent 
PTSD in the population as a whole (but preventing PTSD in women, a higher risk group). Further research 
should build on this by clarifying which sub-groups best respond to pharmacological prevention. 
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We conclude that in individuals with no contraindications to its prescription, hydrocortisone could be consid-
ered as a preventative intervention for people with severe physical illness or injury, shortly after a traumatic 
event. While there are general indications that hydrocortisone may be effective, questions remain regarding 
the sub-groups most likely to benefit and so more research is needed using larger, high quality RCTs to es-
tablish the most efficacious use of hydrocortisone in different populations and optimal dosing, dosing win-
dow and route. Future research should also clarify other pertinent questions, for instance it is possible that 
hydrocortisone may impede declarative memory retrieval53, which could hinder the recall of testimony re-
quired for trauma victims to secure convictions against their perpetrators. Conversely, it is also possible that 
over-consolidation, or shifts in the degree of contextualisation in consolidated memory in PTSD formation 
may affect accurate memory recall with similar implications. In addition, further work is required to consider 
other agents with potential such as oxytocin and opioids, and to develop novel agents informed by our im-
proving neurobiological understanding of PTSD and its development. 
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 Country Trauma Sam-
ple 
Pharmacother-
apy 
Timing after 
trauma 
Comparator n PTSD/ASD Outcome Follow up 
Delahanty et 
al* 
USA Injury Hydrocortisone <12h Placebo 43 PTSD Severity (CAPS) 1, 3 months 
Denke et al* 
Germany Septic Shock Hydrocortisone <6h Placebo 18 PTSD Incidence (PTSS-10) 12 months 
Schelling et 
al* 
Germany Septic Shock Hydrocortisone <6h Placebo 20 PTSD Incidence & Severity 
(SCID-IV & PTSS-10) 
31 months 
Schelling et al 
Germany 
Zohar et al* 
Hydrocortisone <6h Standard ther-
apy 
48 PTSD Severity (PTSS-10) 6 months 
Weis et al* 
Germany Cardiac Sur-
gery 
Hydrocortisone <6h Placebo 28 PTSD Incidence (PTSS-10) 6 months 
Zohar et al* 
Israel Injury Hydrocortisone <6h Placebo 17 PTSD Incidence (CAPS) 3 months 
Kok et al* 
Netherlands Cardiac Sur-
gery 
Dexamethasone <6h Placebo 2458 PTSD Incidence (PTSS-10) 18 - 48 months 
Hoge et al* 
USA Injury Propranolol 4-12h Placebo 41 PTSD Incidence & Severity 
(CAPS) 
1, 3 months 
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Pitman et al* 
USA Injury Propranolol <6h Placebo 24 PTSD Incidence & Severity 
(CAPS) 
1, 3 months 
Stein et al* 
USA Injury Propranolol <48h Placebo 38 ASD Severity & PTSD Inci-
dence (ASDS & PCL-C) 
1, 4, 8 months 
Shalev et al* 
Israel Injury Escitalopram 19.8 days Placebo 36 PTSD Incidence & Severity 
(CAPS) 
5, 9 months 
Suliman et al* 
South Africa Injury Escitalopram <28 days Placebo 29 PTSD Incidence (CAPS) 0.5, 6, 14 
months 
Zohar et al 
Israel/South 
Africa 
Injury Escitalopram <30 days Placebo 198 PTSD Severity (CAPS) 14 months 
Van Zuiden et 
al* 
Netherlands Injury Oxytocin <12 days Placebo 107 PTSD Incidence & Severity 
(CAPS) 
1.5, 3, 6 
months 
Matsuoka et 
al* 
Japan Injury Fish oil 
(1,470mg 
DHA/147mg 
EPA) 
10 days Placebo 110 PTSD Incidence & Severity 
(Clinical Diagnosis & CAPS) 
3 months 
Nishi et al 
Japan Disaster Relief Fish oil (224mg 
DHA/22.4mg 
EPA) 
Not specified Psychoeduca-
tion 
172 PTSD Incidence (IES-R) 12.6 weeks 
* = Included in meta-analysis, PTSD = Post-traumatic Stress Disorder, ASD = Acute Stress Disorder, n = number of participants included at final assessment, CAPS = 
Clinician Administered PTSD Scale,  
PTSS-10 = Post-traumatic 10 Stress Symptom Inventory, IES-R = Impact of Events Scale - Revised, SCID-IV = Structured Clinical Interview for DSM IV, ASDS = 
Acute Stress Disorder Scale,  
PCL-C = PTSD Checklist - Civilian Version 
Table 1: Characteristics of included adult studies 
 
 
 
 
 
 
 
 
Country Trauma 
Sample 
Pharmacotherapy Timing after 
trauma 
Comparator n PTSD/ASD Outcome Follow up 
Nugent* 
USA Injury Propranolol <12h Placebo 20 PTSD Incidence & Severity 
(CAPS-CA) 
6 weeks 
Rosenberg et 
al* 
USA Burns Propranolol <2 days Standard ther-
apy 
197 PTSD Incidence (MAGIC) 7 years 
Robert et al* 
USA Burns Imipramine 36 days Chloral Hydrate 25 ASD Severity (Clinical In-
terview) 
36 days 
* = Included in meta-analysis, PTSD = Post-traumatic Stress Disorder, ASD = Acute Stress Disorder, n = number of participants included at final assessment, 
CAPS-CA = Clinician Administered PTSD Scale for Children & Adolescents, MAGIC = Missouri Assessment of Genetics Interview for Children,  
PTSD Section, DICA = Diagnostic Interview for Children & Adolescents 
Table 2: Characteristics of included child & adolescent studies 
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Pharmacotherapy Outcome 
Comparisons Participants (n) RR/SMD (95% CI) I2  GRADE Judgement 
Hydrocortisone PTSD 3-6 Months 
3 98 RR: 0.21 (0.05 to 
0.89) 
0% Low 
Hydrocortisone PTSD Severity 3-6 Months 
1 43 SMD: -0.63 (-1.25 
to -0.02) 
N/A Very low 
Hydrocortisone PTSD >6 Months 
2 38 RR: 0.44 (0.16 to 
1.23) 
59% Very low 
Dexamethasone PTSD 18-48 Months 
1 2458 RR: 0.80 (0.56 to 
1.14) 
N/A Very low 
Propranolol 
PTSD 3-6 Months 3 96 RR: 0.75 (0.31 to 
1.83) 
0% Low 
Propranolol 
PTSD Severity 3-6 Months 2 52 SMD: 0.06 (-0.49 to 
0.61) 
0% Low 
Escitalopram 
(treatment not 
prevention) 
PTSD 3-6 Months 2 92 RR: 1.05 (0.61 to 
1.79) 
0% Low 
Escitalopram 
(treatment not 
prevention) 
PTSD Severity 3-6 Months 2 68 SMD: -0.01 (-0.49 
to 0.47) 
0% Low 
Gabapentin* 
PTSD 3-6 Months 1 32 RR: 0.80 (0.18 to 
3.59) 
N/A Very low 
Oxytocin* 
PTSD Severity 3-6 Months 1 107 SMD: -0.24 (-0.62 
to 0.14) 
N/A Very low 
Fish oil (1,470mg 
DHA/147mg EPA)* 
PTSD 0-3 Months 1 110 RR: 2.15 (0.20 to 
23.04) 
N/A Very Low 
PTSD = Post-traumatic Stress Disorder, n = number of participants included at final assessment, RR = relative risk,  
SMD = standard mean difference, CI = confidence interval, *only one study for outcome so data not pooled 
Table 3: Effects of pharmacotherapy for PTSD prevention in adult participant RCTs 
 
 
 
 
 
 
 
Pharmacotherapy Outcome 
Comparisons Participants (n) RR/SMD (95% CI) I2  GRADE Judgement 
Propranolol 
PTSD Severity 1-3 Months 1 20 SMD: 0.01 (-0.87 to 
0.89) 
N/A Very low 
Propranolol 
PTSD 1 Month -7 Years 2 217 RR: 0.48 (0.13 to 
1.77) 
N/A Very low 
Imipramine (vs chloral hy-
drate) 
ASD Severity 0-7 Days 1 25 RR: 2.17 (1.04 to 
4.51) 
N/A Very low 
PTSD = Post-traumatic Stress Disorder, ASD = Acute Stress Disorder,  n = number of participants included at final assessment, RR = relative risk,  
SMD = standard mean difference, CI = confidence interval 
Table 4: Effects of pharmacotherapy for PTSD prevention in child and adolescent participant RCTs 
 
 
 
